JNJ Stock Recent News

JNJ LATEST HEADLINES

JNJ Stock News Image - fool.com

Some of the best dividend stocks in the world are on sale right now. Shares of Federal Realty Investment Trust (FRT -0.30%), Johnson & Johnson (JNJ -0.56%), and PepsiCo (PEP -0.56%) are currently down 8% to 27% from their 52-week highs.

fool.com 2025 May 29
JNJ Stock News Image - businesswire.com

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 16th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & J.

businesswire.com 2025 May 28
JNJ Stock News Image - seekingalpha.com

Johnson & Johnson (NYSE:JNJ ) Bernstein's 41st Annual Strategic Decisions Conference Call May 28, 2025 9:00 AM ET Company Participants Joaquin Duato - Chairman and Chief Executive Officer Joseph Wolk - Executive Vice President, Chief Financial Officer Conference Call Participants Lee Hambright - Bernstein Lee Hambright All right, thank you, everybody. Thanks, guys.

seekingalpha.com 2025 May 28
JNJ Stock News Image - seekingalpha.com

Market uncertainty and muted returns in 2025 make portfolio stability and income reliability crucial; dividend stocks are key for navigating volatility. General Mills offers a well-covered 4.4% yield, strong fundamentals, and attractive long-term value despite near-term headwinds and potential price weakness. Kenvue, with a 3.4% yield and resilient performance post-spin-off, provides stability and potential for gradual dividend growth and price appreciation.

seekingalpha.com 2025 May 28
JNJ Stock News Image - seekingalpha.com

Despite legal headwinds and a declining share price, JNJ remains a financial powerhouse with strong profitability, a robust dividend, and aggressive buybacks. JNJ's 62-year streak of dividend growth, 3.4% yield, and disciplined capital allocation make it highly attractive for long-term, income-focused investors. The company is undervalued, trading at less than 15x 2025 EPS, with double-digit EPS growth projected and a pipeline of high-growth assets fueling future expansion.

seekingalpha.com 2025 May 27
JNJ Stock News Image - fool.com

There are hundreds of dividend stocks on the market, but they don't all offer the same level of security. Some haven't increased their payouts in years.

fool.com 2025 May 27
JNJ Stock News Image - seekingalpha.com

I maintain my buy rating on JNJ, citing attractive valuation, improved technicals, and a raised intrinsic value target of $184 per share. JNJ's recent earnings beat expectations, with strong Medicine and MedTech growth, a 63rd consecutive dividend hike, and healthy free cash flow. Litigation headwinds are easing, and management raised revenue guidance, though they remain cautious on earnings due to tariffs and acquisitions.

seekingalpha.com 2025 May 27
JNJ Stock News Image - seekingalpha.com

I love luxury watches, but buying more to "earn" access to rarer models made me realize how easy it is to waste capital chasing ego-driven goals. Unlike watches, dividend growth stocks offer reliable long-term returns. A $10K McDonald's investment in 2004 would've yielded over $22K in dividends alone. History shows that strong-yielding dividend stocks, especially those in the second quintile, have consistently outperformed the market with lower risk.

seekingalpha.com 2025 May 26
JNJ Stock News Image - fool.com

The Dow Jones Industrial Average is an iconic stock market index. It tracks the performance of 30 of the country's most prominent publicly traded companies.

fool.com 2025 May 24
JNJ Stock News Image - businesswire.com

WASHINGTON--(BUSINESS WIRE)--A panel of medical experts convened by the U.S. Food & Drug Administration urged the agency to study and adopt new standards to prohibit the use of talc in consumer products such as gum, candy, rice and pharmaceuticals. Many of the experts cited the more than 30 years of studies showing an association between talc use and ovarian cancer, which led Johnson & Johnson (NYSE:JNJ) to remove the company's iconic body powders from the market in recent years. “It's.

businesswire.com 2025 May 23
10 of 50